1. Inicio
  2. Sistema de Salut de Catalunya
  3. Envíos recientes

Sistema de Salut de Catalunya: Envíos recientes

Mostrando ítems 401-420 de 9072

    Release of mitochondrial dsRNA into the cytosol is a key driver of the inflammatory phenotype of senescent cells 

    Maus, Mate; Zacharioudakis, Emmanouil; Lafarga, Miguel; Madeira Marques, Francisco; López Polo, Vanessa; Stephan-Otto Attolini, Camille (Fecha de publicación: 2025-02-18)

    Mitochondrial dsRNA; Cytosol; Inflammatory phenotype

    Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 

    Schettini, Francesco; Giuliano, Mario; Bartsch, Rupert; Pinato, David James; Onesti, Concetta Elisa; Cortés Castan, Javier; Lambertini, Matteo (Fecha de publicación: 2022-03-15)

    Antraciclines; Càncer de mama; Receptor hormonal

    A combinatorial culture strategy to develop pseudomyxoma peritonei organoid models 

    Varinelli, Luca; Di Bella, Marzia; Guaglio, Marcello; Battistessa, Davide; Pisati, Federica; Cavalleri, Tommaso; Martinez-Quintanilla, Jordi (Fecha de publicación: 2025-02-18)

    Appendiceal tumors; Organoids; Pseudomyxoma peritonei

    Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy 

    Somara, Sasikala; Ko, Heidi; Thatai, Purva; Wallen, Zachary; Saini, Kamal S.; Quintana, Angela (Fecha de publicación: 2024-12-04)

    Diagnostic biomarker; Head and neck cancer; Squamous cell cancer

    Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy 

    Reinisch, Mattea; Bruzas, Simona; Gluz, Oleg; Ataseven, Beyhan; Schmid, Peter; Cortes, Javier (Fecha de publicación: 2023-07-05)

    Adjuvant chemotherapy; Early breast cancer; Lymph node-positive

    Young oncologists' perspective on the role and future of the clinician-scientist in oncology 

    Lim, Kok Haw Jonathan; Westphalen, Benedikt; Berghoff, Anna Sophie; Cardone, Claudia; Connolly, E. A.; Guven, Deniz Can; Mateo, Joaquin (Fecha de publicación: 2023-09-14)

    Jóvenes oncólogos; Oncología

    Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers 

    Thomas-Black, Gilbert; Altmann, Daniel; Crook, Harry; Solanky, Nita; Battiston, Marco; Grussu, Francesco; Prados Carrasco, Ferran (Fecha de publicación: 2023-10-09)

    Friedreich's ataxia; MRI; Biomarkers

    Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial 

    Adamo, Barbara; Pascual, Tomás; Vidal, Maria; Pérez Fidalgo, José A; Gómez Pardo, Patricia; Paré, Laia; Bellet Ezquerra, Meritxell (Fecha de publicación: 2020-07-08)

    Breast cancer; Metronomic; Vinorelbine

    Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial 

    de la Fuente, Macarena; Colman, Howard; Rosenthal, Mark; Van Tine, Brian; Levacic, Danijela; Walbert, Tobias; Vieito Villar, Maria (Fecha de publicación: 2023-02-14)

    Brain penetration; Mutant; Olutasidenib

    Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI) 

    Canaro Hirnyk, Mariana; Sánchez-González, Blanca; Álvarez Román, María Teresa; Bárez-García, Abelardo; Bernardo, Angel; Mingot Castellano, María Eva; VALCARCEL, DAVID (Fecha de publicación: 2023-11-10)

    Glucocorticoids; Intravenous immunoglobulins; Primary immune thrombocytopenia

    Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma 

    Sepúlveda, Juan Manuel; Vieito Villar, Maria; Hernández-Guerrero, T.; Doger, B.; Saavedra Gadea, Omar; Braña Garcia, Irene; Moreno, Victor (Fecha de publicación: 2021-09-16)

    Inhibidor de BET; Limfoma no Hodgkin; Tumors sòlids

    Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201 

    Banerjee, Susana; Van Nieuwenhuysen, Els; D'Hondt, Veronique; Monk, Bradley; Clamp, Andrew; Aghajanian, Carol; OAKNIN, ANA (Fecha de publicación: 2025-09-16)

    Efficacy; Safety; Serous ovarian cancer

    HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 

    DIECI, MARIA VITTORIA; Griguolo, Gaia; Marín-Aguilera, Mercedes; GUARNERI, VALENTINA; Brasó Maristany, Fara; Paré, Laia; Vivancos, Ana (Fecha de publicación: 2023-05-17)

    Biomarker; Breast cancer; Gene expression

    Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment 

    Glaviano, Antonino; Wander, Seth; Baird, Richard; Yap, Kenneth C. H.; Lam, Hiu Yan; Toi, Masakazu; Serra, Violeta (Fecha de publicación: 2024-07-04)

    CDK4/6i resistance; Endocrine therapy; Breast cancer

    Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer 

    Ros Montañá, Fco. Javier; Baraibar Argota, Iosune; Salva Ballabrera, Francesc; Tabernero Caturla, Josep; Elez Fernandez, Mª Elena; Saoudi Gonzalez, Nadia (Fecha de publicación: 2022-10-26)

    BRAF mutation; Cetuximab; Colorectal cancer

    A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer 

    Pascual, Tomás; Martin, Miguel; Fernández-Martínez, Aranzazu; Alba, Emilio; Rodríguez-Lescure, Álvaro; Cortés Castan, Javier; Paré, Laia (Fecha de publicación: 2021-03-19)

    No luminal; Subtipus intrínsec; Càncer de mama

    PCIG: a web-based application to explore immune–genomics interactions across cancer types 

    Franch-Exposito, Sebastia; Lahoz, Sara; Esteban-Fabró, Roger; Bassaganyas, Laia; Camps, Jordi; Dienstmann, Rodrigo; Pedrola Gómez, Anna (Fecha de publicación: 2022-07-20)

    Cancer; Application; Genomic alterations

    Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer 

    Forde, Patrick; Spicer, Jonathan; provencio, mariano; Mitsudomi, Tetsuya; Awad, Mark; Lu, Shun; FELIP, ENRIQUETA (Fecha de publicación: 2023-08-02)

    Immunotherapy; Neoadjuvant treatment; Presurgery treatment

    Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer 

    ZENG, Qinghe; genestie, catherine; Rouleau, Etienne; de Bruyn, Marco; Grau Bejar, Juan Francisco; Yaniz-Galende, Elisa; OAKNIN, ANA (Fecha de publicación: 2024-07-05)

    Biomarcador; Inhibidores del punto de control inmunitario; Microambiente tumoral

    Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer 

    Hammarström, Klara; Nunes, Luis; Mathot, Lucy; Lundin, Emma; Korsavidou Hult, Nafsika Dimitra; Mezheyeuski, Artur (Fecha de publicación: 2024-05-22)

    Neoadjuvant therapy; Prognosis; Rectal cancer